Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Avrobio participates in a conference call with Cowen » 16:15
07/09/20
07/09
16:15
07/09/20
16:15
AVRO

Avrobio

$17.44 /

-0.01 (-0.06%)

Biotech Analyst Baral…

Biotech Analyst Baral holds a conference call with management on July 14 at 1 pm hosted by Cowen.

ShowHide Related Items >><<
AVRO Avrobio
$17.44 /

-0.01 (-0.06%)

AVRO Avrobio
$17.44 /

-0.01 (-0.06%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
AVRO Avrobio
$17.44 /

-0.01 (-0.06%)

  • 13
    Feb
  • 17
    Jul
Monday
Hot Stocks
Avrobio doses new patients in Gaucher disease, cystinosis clinical trials » 07:14
07/06/20
07/06
07:14
07/06/20
07:14
AVRO

Avrobio

$17.79 /

-0.05 (-0.28%)

AVROBIO announced that…

AVROBIO announced that the first patient has been dosed in the company's GuardOne clinical trial, a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1. AVROBIO said in a release, "The company also announced that the second patient has been dosed in the ongoing investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis. The company's Phase 1/2 trial of AVR-RD-02 for Gaucher disease type 1 is currently recruiting patients in Australia and Canada, with new clinical sites expected to open in the U.S. and Israel by year-end. The second patient has been dosed in the company's AVR-RD-04 investigational gene therapy program for cystinosis. The ongoing Phase 1/2 clinical trial is sponsored by the company's academic collaborators at the University of California, San Diego and is led by Stephanie Cherqui, Ph.D., associate professor of pediatrics at UCSD. The Phase 1/2 clinical trial is evaluating the safety and efficacy of AVR-RD-04 in patients at least 18 years of age who are currently being treated with cysteamine. The trial will enroll up to six patients. AVR-RD-04 starts with the patient's own hematopoietic stem cells, which are genetically modified to produce functional cystinosin, the protein that is deficient in cystinosis."

ShowHide Related Items >><<
AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

  • 13
    Feb
  • 17
    Jul
Over a month ago
Conference/Events
American Society of Gene & Cell Therapy to hold virtual meeting » 05:55
05/15/20
05/15
05:55
05/15/20
05:55
A

Agilent

$81.59 /

+1.44 (+1.80%)

, ABEO

Abeona Therapeutics

$3.21 /

-0.065 (-1.98%)

, ADVM

Adverum Biotechnologies

$17.20 /

-0.18 (-1.04%)

, AGEEF

Halo Labs

$0.00 /

+ (+0.00%)

, AVRO

Avrobio

$15.58 /

-1.19 (-7.10%)

, BIO

Bio-Rad

$455.80 /

+2.52 (+0.56%)

, BMRN

BioMarin

$91.67 /

-3.01 (-3.18%)

, CRL

Charles River

$163.30 /

+3.07 (+1.92%)

, CTLT

Catalent

$70.04 /

-1.08 (-1.52%)

, MGTA

Magenta Therapeutics

$8.67 /

-0.305 (-3.40%)

, PI

Impinj

$22.94 /

+1.01 (+4.61%)

, QURE

uniQure

$56.16 /

-0.56 (-0.99%)

, SRPT

Sarepta

$127.15 /

-1.08 (-0.84%)

, TECH

Bio-Techne

$261.68 /

-0.7 (-0.27%)

, TMO

Thermo Fisher

$336.49 /

+2.31 (+0.69%)

, RARE

Ultragenyx

$64.57 /

+0.44 (+0.69%)

23rd Annual Virtual…

23rd Annual Virtual Meeting of ASGCT 2020 will be held May 12-15. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

TECH Bio-Techne
$261.68 /

-0.7 (-0.27%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

RARE Ultragenyx
$64.57 /

+0.44 (+0.69%)

QURE uniQure
$56.16 /

-0.56 (-0.99%)

PI Impinj
$22.94 /

+1.01 (+4.61%)

MGTA Magenta Therapeutics
$8.67 /

-0.305 (-3.40%)

CTLT Catalent
$70.04 /

-1.08 (-1.52%)

CRL Charles River
$163.30 /

+3.07 (+1.92%)

BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

BIO Bio-Rad
$455.80 /

+2.52 (+0.56%)

AVRO Avrobio
$15.58 /

-1.19 (-7.10%)

ADVM Adverum Biotechnologies
$17.20 /

-0.18 (-1.04%)

ABEO Abeona Therapeutics
$3.21 /

-0.065 (-1.98%)

A Agilent
$81.59 /

+1.44 (+1.80%)

A Agilent
$81.59 /

+1.44 (+1.80%)

03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
ABEO Abeona Therapeutics
$3.21 /

-0.065 (-1.98%)

05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
ADVM Adverum Biotechnologies
$17.20 /

-0.18 (-1.04%)

05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
04/28/20 Goldman Sachs
Adverum Biotechnologies initiated with a Buy at Goldman Sachs
AGEEF Halo Labs
$0.00 /

+ (+0.00%)

AVRO Avrobio
$15.58 /

-1.19 (-7.10%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BIO Bio-Rad
$455.80 /

+2.52 (+0.56%)

04/08/20 Jefferies
Bio-Rad COVID-19 antibody test 'could be big,' says Jefferies
03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
CRL Charles River
$163.30 /

+3.07 (+1.92%)

05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
04/21/20 Jefferies
Jefferies downgrades Charles River to Hold after 51% rally from lows
CTLT Catalent
$70.04 /

-1.08 (-1.52%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MGTA Magenta Therapeutics
$8.67 /

-0.305 (-3.40%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
PI Impinj
$22.94 /

+1.01 (+4.61%)

04/28/20 Needham
Impinj price target raised to $25 from $19 at Needham
04/28/20 Canaccord
Impinj price target lowered to $35 from $40 at Canaccord
04/27/20 Piper Sandler
Impinj price target lowered to $29 from $44 at Piper Sandler
03/10/20 Morgan Stanley
Morgan Stanley lowers semiconductor estimates to reflect COVID-19 disruption
QURE uniQure
$56.16 /

-0.56 (-0.99%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

05/07/20 Nomura Instinet
Nomura sees double in Sarepta shares, says buy on earnings selloff
04/28/20 JMP Securities
JMP cautious on feasibility of Sarepta PPMO constructs being used in COVID fight
04/27/20 Citi
Sarepta upcoming PPMO readout unlikely to be catalyst, says Citi
03/30/20 Mizuho
Sarepta initiated with a Buy at Mizuho
TECH Bio-Techne
$261.68 /

-0.7 (-0.27%)

05/14/20 Benchmark
Benchmark sees 'multiple ways to play COVID-19' for Bio-Techne, starts at Buy
05/14/20 Benchmark
Bio-Techne initiated with a Buy at Benchmark
04/20/20 Craig-Hallum
Bio-Techne price target lowered to $211 from $218 at Craig-Hallum
03/30/20 Wells Fargo
Bio-Techne price target lowered to $190 from $225 at Wells Fargo
TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

04/23/20 SVB Leerink
Thermo Fisher price target raised to $365 from $330 at SVB Leerink
04/23/20 Needham
Thermo Fisher price target raised to $383 from $341 at Needham
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
03/30/20 Wells Fargo
Thermo Fisher price target lowered to $300 from $345 at Wells Fargo
RARE Ultragenyx
$64.57 /

+0.44 (+0.69%)

05/13/20 Piper Sandler
Ultragenyx DTX-301 update 'incrementally positive,' says Piper Sandler
01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

TECH Bio-Techne
$261.68 /

-0.7 (-0.27%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

RARE Ultragenyx
$64.57 /

+0.44 (+0.69%)

QURE uniQure
$56.16 /

-0.56 (-0.99%)

PI Impinj
$22.94 /

+1.01 (+4.61%)

MGTA Magenta Therapeutics
$8.67 /

-0.305 (-3.40%)

CTLT Catalent
$70.04 /

-1.08 (-1.52%)

CRL Charles River
$163.30 /

+3.07 (+1.92%)

BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

BIO Bio-Rad
$455.80 /

+2.52 (+0.56%)

AVRO Avrobio
$15.58 /

-1.19 (-7.10%)

ADVM Adverum Biotechnologies
$17.20 /

-0.18 (-1.04%)

ABEO Abeona Therapeutics
$3.21 /

-0.065 (-1.98%)

A Agilent
$81.59 /

+1.44 (+1.80%)

TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

CTLT Catalent
$70.04 /

-1.08 (-1.52%)

A Agilent
$81.59 /

+1.44 (+1.80%)

TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

PI Impinj
$22.94 /

+1.01 (+4.61%)

BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

ADVM Adverum Biotechnologies
$17.20 /

-0.18 (-1.04%)

A Agilent
$81.59 /

+1.44 (+1.80%)

TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

QURE uniQure
$56.16 /

-0.56 (-0.99%)

PI Impinj
$22.94 /

+1.01 (+4.61%)

BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

A Agilent
$81.59 /

+1.44 (+1.80%)

Conference/Events
American Society of Gene & Cell Therapy to hold virtual meeting » 04:55
05/14/20
05/14
04:55
05/14/20
04:55
A

Agilent

$80.15 /

+0.32 (+0.40%)

, ABEO

Abeona Therapeutics

$3.28 /

+0.235 (+7.73%)

, ADVM

Adverum Biotechnologies

$17.38 /

-1.4 (-7.45%)

, AGEEF

Halo Labs

$0.00 /

+ (+0.00%)

, AVRO

Avrobio

$16.77 /

-0.22 (-1.29%)

, BIO

Bio-Rad

$453.28 /

-8.19 (-1.77%)

, BMRN

BioMarin

$94.68 /

-1.49 (-1.55%)

, CRL

Charles River

$160.23 /

-1.16 (-0.72%)

, CTLT

Catalent

$71.12 /

+ (+0.00%)

, MGTA

Magenta Therapeutics

$8.98 /

-0.4 (-4.27%)

, PI

Impinj

$21.93 /

-1.94 (-8.13%)

, QURE

uniQure

$56.72 /

-4.33 (-7.09%)

, SRPT

Sarepta

$128.23 /

-4.5 (-3.39%)

, TECH

Bio-Techne

$262.38 /

-10.54 (-3.86%)

, TMO

Thermo Fisher

$334.18 /

+2.23 (+0.67%)

, RARE

Ultragenyx

$64.13 /

-2.07 (-3.13%)

23rd Annual Virtual…

23rd Annual Virtual Meeting of ASGCT 2020 will be held May 12-15. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

TECH Bio-Techne
$262.38 /

-10.54 (-3.86%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

RARE Ultragenyx
$64.13 /

-2.07 (-3.13%)

QURE uniQure
$56.72 /

-4.33 (-7.09%)

PI Impinj
$21.93 /

-1.94 (-8.13%)

MGTA Magenta Therapeutics
$8.98 /

-0.4 (-4.27%)

CTLT Catalent
$71.12 /

+ (+0.00%)

CRL Charles River
$160.23 /

-1.16 (-0.72%)

BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

BIO Bio-Rad
$453.28 /

-8.19 (-1.77%)

AVRO Avrobio
$16.77 /

-0.22 (-1.29%)

ADVM Adverum Biotechnologies
$17.38 /

-1.4 (-7.45%)

ABEO Abeona Therapeutics
$3.28 /

+0.235 (+7.73%)

A Agilent
$80.15 /

+0.32 (+0.40%)

A Agilent
$80.15 /

+0.32 (+0.40%)

03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
ABEO Abeona Therapeutics
$3.28 /

+0.235 (+7.73%)

05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
ADVM Adverum Biotechnologies
$17.38 /

-1.4 (-7.45%)

05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
04/28/20 Goldman Sachs
Adverum Biotechnologies initiated with a Buy at Goldman Sachs
AGEEF Halo Labs
$0.00 /

+ (+0.00%)

AVRO Avrobio
$16.77 /

-0.22 (-1.29%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BIO Bio-Rad
$453.28 /

-8.19 (-1.77%)

04/08/20 Jefferies
Bio-Rad COVID-19 antibody test 'could be big,' says Jefferies
03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
CRL Charles River
$160.23 /

-1.16 (-0.72%)

05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
04/21/20 Jefferies
Jefferies downgrades Charles River to Hold after 51% rally from lows
CTLT Catalent
$71.12 /

+ (+0.00%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MGTA Magenta Therapeutics
$8.98 /

-0.4 (-4.27%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
PI Impinj
$21.93 /

-1.94 (-8.13%)

04/28/20 Needham
Impinj price target raised to $25 from $19 at Needham
04/28/20 Canaccord
Impinj price target lowered to $35 from $40 at Canaccord
04/27/20 Piper Sandler
Impinj price target lowered to $29 from $44 at Piper Sandler
03/10/20 Morgan Stanley
Morgan Stanley lowers semiconductor estimates to reflect COVID-19 disruption
QURE uniQure
$56.72 /

-4.33 (-7.09%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

05/07/20 Nomura Instinet
Nomura sees double in Sarepta shares, says buy on earnings selloff
04/28/20 JMP Securities
JMP cautious on feasibility of Sarepta PPMO constructs being used in COVID fight
04/27/20 Citi
Sarepta upcoming PPMO readout unlikely to be catalyst, says Citi
03/30/20 Mizuho
Sarepta initiated with a Buy at Mizuho
TECH Bio-Techne
$262.38 /

-10.54 (-3.86%)

04/20/20 Craig-Hallum
Bio-Techne price target lowered to $211 from $218 at Craig-Hallum
03/30/20 Wells Fargo
Bio-Techne price target lowered to $190 from $225 at Wells Fargo
02/24/20 Eight Capital
Bio-Techne downgraded to Neutral from Buy at Eight Capital
01/08/20 Stephens
Bio-Techne resumed with an Overweight at Stephens
TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

04/23/20 SVB Leerink
Thermo Fisher price target raised to $365 from $330 at SVB Leerink
04/23/20 Needham
Thermo Fisher price target raised to $383 from $341 at Needham
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
03/30/20 Wells Fargo
Thermo Fisher price target lowered to $300 from $345 at Wells Fargo
RARE Ultragenyx
$64.13 /

-2.07 (-3.13%)

05/13/20 Piper Sandler
Ultragenyx DTX-301 update 'incrementally positive,' says Piper Sandler
01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

TECH Bio-Techne
$262.38 /

-10.54 (-3.86%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

RARE Ultragenyx
$64.13 /

-2.07 (-3.13%)

QURE uniQure
$56.72 /

-4.33 (-7.09%)

PI Impinj
$21.93 /

-1.94 (-8.13%)

MGTA Magenta Therapeutics
$8.98 /

-0.4 (-4.27%)

CTLT Catalent
$71.12 /

+ (+0.00%)

CRL Charles River
$160.23 /

-1.16 (-0.72%)

BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

BIO Bio-Rad
$453.28 /

-8.19 (-1.77%)

AVRO Avrobio
$16.77 /

-0.22 (-1.29%)

ADVM Adverum Biotechnologies
$17.38 /

-1.4 (-7.45%)

ABEO Abeona Therapeutics
$3.28 /

+0.235 (+7.73%)

A Agilent
$80.15 /

+0.32 (+0.40%)

TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

CTLT Catalent
$71.12 /

+ (+0.00%)

A Agilent
$80.15 /

+0.32 (+0.40%)

TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

PI Impinj
$21.93 /

-1.94 (-8.13%)

BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

ADVM Adverum Biotechnologies
$17.38 /

-1.4 (-7.45%)

A Agilent
$80.15 /

+0.32 (+0.40%)

TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

QURE uniQure
$56.72 /

-4.33 (-7.09%)

PI Impinj
$21.93 /

-1.94 (-8.13%)

BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

A Agilent
$80.15 /

+0.32 (+0.40%)

Hot Stocks
Avrobio announces new Fabry disease, cystinosis program data at ASGCT » 07:18
05/13/20
05/13
07:18
05/13/20
07:18
AVRO

Avrobio

$16.99 /

+0.18 (+1.07%)

Avrobio announced new…

Avrobio announced new clinical data from its investigational programs for Fabry disease and cystinosis. The data will be presented at the American Society of Gene & Cell Therapy, or ASGCT. Four patients have been dosed in the Phase 2 trial of AVR-RD-01, Avrobio's investigational lentiviral gene therapy for Fabry disease. The first patient continued to show increased leukocyte and plasma AGA enzyme activity, now up to 22 months post-treatment. These data suggest the patient is producing an endogenous supply of functional alpha-galactosidase, or AGA, enzyme, which is essential to prevent the accumulation of a toxic metabolite, lyso-Gb3, in tissues including the heart and kidneys. A sustained decrease in plasma lyso-Gb3 and total Gb3 levels has previously been reported for this patient out to 18 months. The third patient had a sustained decrease in plasma lyso-Gb3 and total Gb3 levels nine months after dosing. This patient also had a stable vector copy number, or VCN, out approximately one year post-treatment, suggesting successful engraftment. The fourth patient, who is also the first to be dosed with Avrobio's plato gene therapy platform, had a 43% reduction in the toxic metabolite plasma lyso-Gb3 at one month. At three months, he also had leukocyte enzyme and plasma enzyme activity levels approximately three times higher than the mean activity level of the first three patients in the same trial at the same timepoint. While the presentation will focus on data updates for its Phase 2 trial, the company also reports that all three Phase 1 patients who discontinued enzyme replacement therapy, or ERT, after receiving AVR-RD-01 gene therapy, remain off ERT as of April 27. As of the safety data cut-off date of November 26, 2019, there have been no safety events attributed to AVR-RD-01 drug product in either the Phase 1 or Phase 2 trial. Through the safety data cut-off date, four serious adverse events, or SAEs, have been reported in the FAB-201 trial and two SAEs in the Phase 1 trial. The fourth Phase 2 patient, who was dosed after the safety data cut-off date, has reported an SAE, which was not attributed to AVR-RD-01 and which subsequently resolved. Across both studies, each of the SAEs has been consistent with the conditioning regimen, stem cell mobilization, underlying disease or pre-existing conditions. Pre-existing low anti-AGA antibody titers have been detected in four patients in the Phase 1 trial and a transient low titer was observed but not detectable in subsequent measures in one patient in the Phase 2 trial. Avrobio continues to actively identify participants for the Phase 2 Fabry disease trial in Australia, Canada and the U.S. The FAB-201 trial is an ongoing open-label, single-arm Phase 2 clinical trial evaluating the efficacy and safety of AVR-RD-01 in eight to 12 treatment-naive Fabry disease patients. New data will also be presented from the first patient dosed in the investigator-sponsored Phase 1/2 trial of AVR-RD-04 for cystinosis, a progressive disease marked by the accumulation of cystine in cellular organelles known as lysosomes. This buildup can cause debilitating symptoms including kidney failure, corneal damage and thyroid dysfunction, often leading to a shortened lifespan. Currently, more than 90% of treated cystinosis patients require a kidney transplant in the second or third decade of life. The current standard of care for cystinosis is cysteamine, a burdensome treatment regimen that can require dozens of pills per day and may not prevent overall progression of the disease. Six months following administration of AVR-RD-04, the patient's estimated glomerular filtration rate, which is a measure of kidney function, improved from 38 mL/mi/1.73m2 at baseline to 52 mL/mi/1.73m2. The patient's serum creatinine, another measure of kidney function, also improved, falling from 2.2 mg/dL at baseline to 1.6 mg/dL at six months. The patient stopped cysteamine treatment before administration of AVR-RD-04 and remains off cysteamine. As of the safety data cut-off date of January 27, which was approximately three months following administration of the investigational gene therapy to the first patient in the AVR-RD-04 program, there have been no reports of safety events attributed to the investigational drug product. In addition, no SAEs have been reported as of the safety data cut-off date. Adverse events did not suggest any unexpected safety signals or trends.

ShowHide Related Items >><<
AVRO Avrobio
$16.99 /

+0.18 (+1.07%)

AVRO Avrobio
$16.99 /

+0.18 (+1.07%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
AVRO Avrobio
$16.99 /

+0.18 (+1.07%)

Conference/Events
American Society of Gene & Cell Therapy to hold virtual meeting » 04:55
05/13/20
05/13
04:55
05/13/20
04:55
A

Agilent

$79.83 /

-1.49 (-1.83%)

, ABEO

Abeona Therapeutics

$3.04 /

-0.21 (-6.46%)

, ADVM

Adverum Biotechnologies

$18.78 /

-1.06 (-5.34%)

, AGEEF

Halo Labs

$0.00 /

+ (+0.00%)

, AVRO

Avrobio

$16.99 /

+0.18 (+1.07%)

, BIO

Bio-Rad

$461.47 /

-7.6 (-1.62%)

, BMRN

BioMarin

$96.17 /

-0.27 (-0.28%)

, CRL

Charles River

$161.39 /

-3.11 (-1.89%)

, CTLT

Catalent

$71.12 /

-2.12 (-2.89%)

, MGTA

Magenta Therapeutics

$9.38 /

-1.245 (-11.72%)

, PI

Impinj

$23.87 /

-0.73 (-2.97%)

, QURE

uniQure

$61.05 /

+0.78 (+1.29%)

, SRPT

Sarepta

$132.73 /

-3.32 (-2.44%)

, TECH

Bio-Techne

$272.92 /

-7.48 (-2.67%)

, TMO

Thermo Fisher

$331.95 /

-8.42 (-2.47%)

, RARE

Ultragenyx

$66.20 /

-1.17 (-1.74%)

23rd Annual Virtual…

23rd Annual Virtual Meeting of ASGCT 2020 will be held May 12-15. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$331.95 /

-8.42 (-2.47%)

TECH Bio-Techne
$272.92 /

-7.48 (-2.67%)

SRPT Sarepta
$132.73 /

-3.32 (-2.44%)

RARE Ultragenyx
$66.20 /

-1.17 (-1.74%)

QURE uniQure
$61.05 /

+0.78 (+1.29%)

PI Impinj
$23.87 /

-0.73 (-2.97%)

MGTA Magenta Therapeutics
$9.38 /

-1.245 (-11.72%)

CTLT Catalent
$71.12 /

-2.12 (-2.89%)

CRL Charles River
$161.39 /

-3.11 (-1.89%)

BMRN BioMarin
$96.17 /

-0.27 (-0.28%)

BIO Bio-Rad
$461.47 /

-7.6 (-1.62%)

AVRO Avrobio
$16.99 /

+0.18 (+1.07%)

ADVM Adverum Biotechnologies
$18.78 /

-1.06 (-5.34%)

ABEO Abeona Therapeutics
$3.04 /

-0.21 (-6.46%)

A Agilent
$79.83 /

-1.49 (-1.83%)

A Agilent
$79.83 /

-1.49 (-1.83%)

03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
ABEO Abeona Therapeutics
$3.04 /

-0.21 (-6.46%)

05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
ADVM Adverum Biotechnologies
$18.78 /

-1.06 (-5.34%)

05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
04/28/20 Goldman Sachs
Adverum Biotechnologies initiated with a Buy at Goldman Sachs
AGEEF Halo Labs
$0.00 /

+ (+0.00%)

AVRO Avrobio
$16.99 /

+0.18 (+1.07%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BIO Bio-Rad
$461.47 /

-7.6 (-1.62%)

04/08/20 Jefferies
Bio-Rad COVID-19 antibody test 'could be big,' says Jefferies
03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
BMRN BioMarin
$96.17 /

-0.27 (-0.28%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
CRL Charles River
$161.39 /

-3.11 (-1.89%)

05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
04/21/20 Jefferies
Jefferies downgrades Charles River to Hold after 51% rally from lows
04/21/20 Jefferies
Charles River downgraded to Hold from Buy at Jefferies
CTLT Catalent
$71.12 /

-2.12 (-2.89%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MGTA Magenta Therapeutics
$9.38 /

-1.245 (-11.72%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
PI Impinj
$23.87 /

-0.73 (-2.97%)

04/28/20 Needham
Impinj price target raised to $25 from $19 at Needham
04/28/20 Canaccord
Impinj price target lowered to $35 from $40 at Canaccord
04/27/20 Piper Sandler
Impinj price target lowered to $29 from $44 at Piper Sandler
03/10/20 Morgan Stanley
Morgan Stanley lowers semiconductor estimates to reflect COVID-19 disruption
QURE uniQure
$61.05 /

+0.78 (+1.29%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SRPT Sarepta
$132.73 /

-3.32 (-2.44%)

05/07/20 Nomura Instinet
Nomura sees double in Sarepta shares, says buy on earnings selloff
04/28/20 JMP Securities
JMP cautious on feasibility of Sarepta PPMO constructs being used in COVID fight
04/27/20 Citi
Sarepta upcoming PPMO readout unlikely to be catalyst, says Citi
03/30/20 Mizuho
Sarepta initiated with a Buy at Mizuho
TECH Bio-Techne
$272.92 /

-7.48 (-2.67%)

04/20/20 Craig-Hallum
Bio-Techne price target lowered to $211 from $218 at Craig-Hallum
03/30/20 Wells Fargo
Bio-Techne price target lowered to $190 from $225 at Wells Fargo
02/24/20 Eight Capital
Bio-Techne downgraded to Neutral from Buy at Eight Capital
01/08/20 Stephens
Bio-Techne resumed with an Overweight at Stephens
TMO Thermo Fisher
$331.95 /

-8.42 (-2.47%)

04/23/20 SVB Leerink
Thermo Fisher price target raised to $365 from $330 at SVB Leerink
04/23/20 Needham
Thermo Fisher price target raised to $383 from $341 at Needham
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
03/30/20 Wells Fargo
Thermo Fisher price target lowered to $300 from $345 at Wells Fargo
RARE Ultragenyx
$66.20 /

-1.17 (-1.74%)

01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
TMO Thermo Fisher
$331.95 /

-8.42 (-2.47%)

TECH Bio-Techne
$272.92 /

-7.48 (-2.67%)

SRPT Sarepta
$132.73 /

-3.32 (-2.44%)

RARE Ultragenyx
$66.20 /

-1.17 (-1.74%)

QURE uniQure
$61.05 /

+0.78 (+1.29%)

PI Impinj
$23.87 /

-0.73 (-2.97%)

MGTA Magenta Therapeutics
$9.38 /

-1.245 (-11.72%)

CTLT Catalent
$71.12 /

-2.12 (-2.89%)

CRL Charles River
$161.39 /

-3.11 (-1.89%)

BMRN BioMarin
$96.17 /

-0.27 (-0.28%)

BIO Bio-Rad
$461.47 /

-7.6 (-1.62%)

AVRO Avrobio
$16.99 /

+0.18 (+1.07%)

ADVM Adverum Biotechnologies
$18.78 /

-1.06 (-5.34%)

ABEO Abeona Therapeutics
$3.04 /

-0.21 (-6.46%)

A Agilent
$79.83 /

-1.49 (-1.83%)

TMO Thermo Fisher
$331.95 /

-8.42 (-2.47%)

SRPT Sarepta
$132.73 /

-3.32 (-2.44%)

CTLT Catalent
$71.12 /

-2.12 (-2.89%)

A Agilent
$79.83 /

-1.49 (-1.83%)

TMO Thermo Fisher
$331.95 /

-8.42 (-2.47%)

SRPT Sarepta
$132.73 /

-3.32 (-2.44%)

PI Impinj
$23.87 /

-0.73 (-2.97%)

BMRN BioMarin
$96.17 /

-0.27 (-0.28%)

ADVM Adverum Biotechnologies
$18.78 /

-1.06 (-5.34%)

A Agilent
$79.83 /

-1.49 (-1.83%)

TMO Thermo Fisher
$331.95 /

-8.42 (-2.47%)

SRPT Sarepta
$132.73 /

-3.32 (-2.44%)

QURE uniQure
$61.05 /

+0.78 (+1.29%)

PI Impinj
$23.87 /

-0.73 (-2.97%)

BMRN BioMarin
$96.17 /

-0.27 (-0.28%)

A Agilent
$79.83 /

-1.49 (-1.83%)

Conference/Events
American Society of Gene & Cell Therapy to hold virtual meeting » 08:49
05/12/20
05/12
08:49
05/12/20
08:49
A

Agilent

$81.32 /

+1.6 (+2.01%)

, ABEO

Abeona Therapeutics

$3.25 /

+0.56 (+20.82%)

, ADVM

Adverum Biotechnologies

$19.84 /

+0.24 (+1.22%)

, AGEEF

Halo Labs

$0.00 /

+ (+0.00%)

, AVRO

Avrobio

$16.81 /

+2.38 (+16.49%)

, BIO

Bio-Rad

$469.07 /

+12.35 (+2.70%)

, BMRN

BioMarin

$96.44 /

+1.27 (+1.33%)

, CRL

Charles River

$164.50 /

+4.75 (+2.97%)

, CTLT

Catalent

$73.24 /

+1.33 (+1.85%)

, MGTA

Magenta Therapeutics

$10.62 /

-0.235 (-2.16%)

, PI

Impinj

$24.60 /

-0.25 (-1.01%)

, QURE

uniQure

$60.27 /

+0.51 (+0.85%)

, SRPT

Sarepta

$136.05 /

+8.06 (+6.30%)

, TECH

Bio-Techne

$280.40 /

+9.66 (+3.57%)

, TMO

Thermo Fisher

$340.37 /

+8.79 (+2.65%)

, RARE

Ultragenyx

$67.37 /

+3.53 (+5.53%)

23rd Annual Virtual…

23rd Annual Virtual Meeting of ASGCT 2020 will be held May 12-15. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$340.37 /

+8.79 (+2.65%)

TECH Bio-Techne
$280.40 /

+9.66 (+3.57%)

SRPT Sarepta
$136.05 /

+8.06 (+6.30%)

RARE Ultragenyx
$67.37 /

+3.53 (+5.53%)

QURE uniQure
$60.27 /

+0.51 (+0.85%)

PI Impinj
$24.60 /

-0.25 (-1.01%)

MGTA Magenta Therapeutics
$10.62 /

-0.235 (-2.16%)

CTLT Catalent
$73.24 /

+1.33 (+1.85%)

CRL Charles River
$164.50 /

+4.75 (+2.97%)

BMRN BioMarin
$96.44 /

+1.27 (+1.33%)

BIO Bio-Rad
$469.07 /

+12.35 (+2.70%)

AVRO Avrobio
$16.81 /

+2.38 (+16.49%)

ADVM Adverum Biotechnologies
$19.84 /

+0.24 (+1.22%)

ABEO Abeona Therapeutics
$3.25 /

+0.56 (+20.82%)

A Agilent
$81.32 /

+1.6 (+2.01%)

A Agilent
$81.32 /

+1.6 (+2.01%)

03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
ABEO Abeona Therapeutics
$3.25 /

+0.56 (+20.82%)

05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
ADVM Adverum Biotechnologies
$19.84 /

+0.24 (+1.22%)

05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
04/28/20 Goldman Sachs
Adverum Biotechnologies initiated with a Buy at Goldman Sachs
03/16/20 SVB Leerink
SVB Leerink bullish on Adverum Biotechnologies, initiates with an Outperform
AGEEF Halo Labs
$0.00 /

+ (+0.00%)

AVRO Avrobio
$16.81 /

+2.38 (+16.49%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BIO Bio-Rad
$469.07 /

+12.35 (+2.70%)

04/08/20 Jefferies
Bio-Rad COVID-19 antibody test 'could be big,' says Jefferies
03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
BMRN BioMarin
$96.44 /

+1.27 (+1.33%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
CRL Charles River
$164.50 /

+4.75 (+2.97%)

05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
04/21/20 Jefferies
Jefferies downgrades Charles River to Hold after 51% rally from lows
04/21/20 Jefferies
Charles River downgraded to Hold from Buy at Jefferies
CTLT Catalent
$73.24 /

+1.33 (+1.85%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MGTA Magenta Therapeutics
$10.62 /

-0.235 (-2.16%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
PI Impinj
$24.60 /

-0.25 (-1.01%)

04/28/20 Needham
Impinj price target raised to $25 from $19 at Needham
04/28/20 Canaccord
Impinj price target lowered to $35 from $40 at Canaccord
04/27/20 Piper Sandler
Impinj price target lowered to $29 from $44 at Piper Sandler
03/10/20 Morgan Stanley
Morgan Stanley lowers semiconductor estimates to reflect COVID-19 disruption
QURE uniQure
$60.27 /

+0.51 (+0.85%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SRPT Sarepta
$136.05 /

+8.06 (+6.30%)

05/07/20 Nomura Instinet
Nomura sees double in Sarepta shares, says buy on earnings selloff
04/28/20 JMP Securities
JMP cautious on feasibility of Sarepta PPMO constructs being used in COVID fight
04/27/20 Citi
Sarepta upcoming PPMO readout unlikely to be catalyst, says Citi
03/30/20 Mizuho
Sarepta initiated with a Buy at Mizuho
TECH Bio-Techne
$280.40 /

+9.66 (+3.57%)

04/20/20 Craig-Hallum
Bio-Techne price target lowered to $211 from $218 at Craig-Hallum
03/30/20 Wells Fargo
Bio-Techne price target lowered to $190 from $225 at Wells Fargo
02/24/20 Eight Capital
Bio-Techne downgraded to Neutral from Buy at Eight Capital
01/08/20 Stephens
Bio-Techne resumed with an Overweight at Stephens
TMO Thermo Fisher
$340.37 /

+8.79 (+2.65%)

04/23/20 SVB Leerink
Thermo Fisher price target raised to $365 from $330 at SVB Leerink
04/23/20 Needham
Thermo Fisher price target raised to $383 from $341 at Needham
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
03/30/20 Wells Fargo
Thermo Fisher price target lowered to $300 from $345 at Wells Fargo
RARE Ultragenyx
$67.37 /

+3.53 (+5.53%)

01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
TMO Thermo Fisher
$340.37 /

+8.79 (+2.65%)

TECH Bio-Techne
$280.40 /

+9.66 (+3.57%)

SRPT Sarepta
$136.05 /

+8.06 (+6.30%)

RARE Ultragenyx
$67.37 /

+3.53 (+5.53%)

QURE uniQure
$60.27 /

+0.51 (+0.85%)

PI Impinj
$24.60 /

-0.25 (-1.01%)

MGTA Magenta Therapeutics
$10.62 /

-0.235 (-2.16%)

CTLT Catalent
$73.24 /

+1.33 (+1.85%)

CRL Charles River
$164.50 /

+4.75 (+2.97%)

BMRN BioMarin
$96.44 /

+1.27 (+1.33%)

BIO Bio-Rad
$469.07 /

+12.35 (+2.70%)

AVRO Avrobio
$16.81 /

+2.38 (+16.49%)

ADVM Adverum Biotechnologies
$19.84 /

+0.24 (+1.22%)

ABEO Abeona Therapeutics
$3.25 /

+0.56 (+20.82%)

A Agilent
$81.32 /

+1.6 (+2.01%)

TMO Thermo Fisher
$340.37 /

+8.79 (+2.65%)

SRPT Sarepta
$136.05 /

+8.06 (+6.30%)

CTLT Catalent
$73.24 /

+1.33 (+1.85%)

A Agilent
$81.32 /

+1.6 (+2.01%)

TMO Thermo Fisher
$340.37 /

+8.79 (+2.65%)

SRPT Sarepta
$136.05 /

+8.06 (+6.30%)

PI Impinj
$24.60 /

-0.25 (-1.01%)

BMRN BioMarin
$96.44 /

+1.27 (+1.33%)

ADVM Adverum Biotechnologies
$19.84 /

+0.24 (+1.22%)

A Agilent
$81.32 /

+1.6 (+2.01%)

TMO Thermo Fisher
$340.37 /

+8.79 (+2.65%)

SRPT Sarepta
$136.05 /

+8.06 (+6.30%)

QURE uniQure
$60.27 /

+0.51 (+0.85%)

PI Impinj
$24.60 /

-0.25 (-1.01%)

BMRN BioMarin
$96.44 /

+1.27 (+1.33%)

A Agilent
$81.32 /

+1.6 (+2.01%)

Earnings
Avrobio reports Q1 EPS (77c), consensus (67c) » 07:42
05/07/20
05/07
07:42
05/07/20
07:42
AVRO

Avrobio

$15.25 /

-0.55 (-3.48%)

"Our strong progress…

"Our strong progress has continued, as evidenced by recently announced collaborations with Saladax Biomedical, Inc. and Magenta Therapeutics, which highlight our commitment to leading innovation in the lentiviral gene therapy field and continually evaluating new technologies that potentially complement our state-of-the-art plato gene therapy platform," said Geoff MacKay, AVROBIO's president and CEO. "In addition, while the COVID-19 pandemic has impacted all of us in the biopharma industry, we're glad to report that AVROBIO's essential laboratory and manufacturing activities remain uninterrupted and patient identification activities continue for our clinical trials in Canada, Australia and the U.S. We're in a strong financial position, having raised gross proceeds of $100 million through a follow-on common stock offering in February, and we have extended our cash runway into the second half of 2022. At ASGCT next week, we look forward to sharing new data from our clinical programs in Fabry disease and cystinosis, as well as from our preclinical program in Pompe disease. We expect to provide further data updates on our clinical programs in the second half of 2020."

ShowHide Related Items >><<
AVRO Avrobio
$15.25 /

-0.55 (-3.48%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
Hot Stocks
Magenta Therapeutics, Avrobio announce MGTA-117 collaboration agreement » 07:35
05/06/20
05/06
07:35
05/06/20
07:35
MGTA

Magenta Therapeutics

$8.64 /

-0.34 (-3.79%)

, AVRO

Avrobio

$15.80 /

+2.19 (+16.09%)

Magenta Therapeutics…

Magenta Therapeutics (MGTA) and Avrobio (AVRO) announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta's novel targeted antibody-drug conjugate, or ADC, for conditioning patients before they receive one of Avrobio's investigational lentiviral gene therapies. The collaboration will combine Magenta's expertise in ADC-based conditioning with Avrobio's expertise in lentiviral gene therapies and is expected to further the two companies' shared mission to enable patients to live free from disease. Under the collaboration, Magenta and Avrobio will jointly evaluate MGTA-117 in conjunction with one or more of Avrobio's investigational gene therapies. Magenta will retain all commercial rights to MGTA-117. Avrobio will retain all commercial rights to its gene therapies and will be responsible for the clinical trial costs related to the evaluation of MGTA-117 with Avrobio's gene therapies.

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$8.64 /

-0.34 (-3.79%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
AVRO Avrobio
$15.80 /

+2.19 (+16.09%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
Hot Stocks
Avrobio, Saladax to develop fully automated nanoparticle immunoassay kit » 07:17
05/04/20
05/04
07:17
05/04/20
07:17
AVRO

Avrobio

$13.05 /

+0.2 (+1.56%)

Avrobio announced a new…

Avrobio announced a new development and commercialization agreement with Saladax Biomedical to develop and validate a fully automated nanoparticle immunoassay kit designed to simplify and streamline therapeutic drug monitoring, or TDM, for patients treated with the conditioning agent busulfan. The technology used to deliver these rapid test results is based on an intellectual property portfolio developed by Saladax in the field of TDM. The new assay kit under development by Saladax, which collects a small blood sample, is able to return results on patient metabolization of busulfan in minutes using hospitals' standard analytical devices, expanding access to personalized conditioning with busulfan.

ShowHide Related Items >><<
AVRO Avrobio
$13.05 /

+0.2 (+1.56%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.